Dogwood Therapeutics (DWTX) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
30 Oct, 2026Company overview and business model
Development-stage biopharma focused on medicines for cancer-treatment pain and peripheral neuropathy, with potential expansion into other pain conditions after clinical success.
Halneuron, a NaV 1.7 modulator, is in Phase 2b for chronic pain after cancer chemotherapy; it has FDA Fast Track designation and prior Phase 2 evidence of pain reduction with an acceptable safety profile.
SP16, a proprietary immunomodulatory and anti-inflammatory peptide, is poised to enter Phase 1 for chemotherapy-induced peripheral neuropathy; preclinical findings suggest potential neuroprotective effects.
Financial performance and metrics
Forvis Mazars’ audit report on FY2025 and FY2024 consolidated financial statements contains an explanatory paragraph citing substantial doubt about the ability to continue as a going concern.
Use of proceeds and capital allocation
The October 19, 2026 private placement generated approximately $5.0 million gross proceeds at $1.22 per share; proceeds are intended for general working capital.
No proceeds will be received from Sealbond’s resales under this prospectus; the selling stockholder receives resale proceeds and pays its brokerage fees, commissions and similar selling expenses.
Registration fees and expenses are payable by the issuer; estimated registration costs total $53,897.56, including legal, audit and transfer-agent expenses.
Latest events from Dogwood Therapeutics
- Halneuron® Phase 2b results are due in November; financing extends runway through Q1 2027.DWTX
Q3 2026 - Halneuron delivers significant, durable pain relief in cancer neuropathy with strong clinical progress.DWTX
Corporate presentation - A novel, scalable NaV1.7 inhibitor shows durable efficacy for chemotherapy-induced neuropathic pain.DWTX
KOL event - Q2 2026 net loss reached $11.5M as CINP trial nears completion; cash runway into Q4 2026.DWTX
Q2 2026 - Halneuron delivers significant, durable pain relief for cancer patients with a strong safety profile.DWTX
Corporate presentation - Halneuron® and SP16 advance as first-in-class non-opioid pain therapies targeting major unmet needs.DWTX
Corporate presentation - Pipeline advances, narrowed net loss, and cash runway into Q4 2026; more funding needed.DWTX
Q1 2026 - Halneuron® delivers significant pain relief in CINP, with pivotal data expected Fall 2026.DWTX
Corporate presentation - Halneuron and SP16 progress in clinical trials for chemotherapy-induced neuropathy and pain.DWTX
Study Update